News
CLDI
0.2482
+9.10%
0.0207
Weekly Report: what happened at CLDI last week (0513-0517)?
Weekly Report · 21h ago
Calidi Biotherapeutics Enhances Executive Compensation Package
TipRanks · 3d ago
David LaPre Resigns from Calidi Biotherapeutics Board
TipRanks · 4d ago
Calidi Biotherapeutics Is Maintained at Outperform by Baird
Dow Jones · 5d ago
Calidi Biotherapeutics Price Target Cut to $2.00/Share From $4.50 by Baird
Dow Jones · 5d ago
Baird Maintains Outperform on Calidi Biotherapeutics, Lowers Price Target to $2
Benzinga · 5d ago
Calidi Biotherapeutics reports Q1 results
Seeking Alpha · 5d ago
Calidi Biotherapeutics Clarifies Disclosure’s Legal Standing
TipRanks · 5d ago
CLDI Stock Earnings: Calidi Biotherapeutics Beats EPS for Q1 2024
Investorplace · 6d ago
Calidi Biotherapeutics Q1 2024 Adj EPS $(0.20) Beats $(0.28) Estimate
Benzinga · 6d ago
Press Release: Calidi Biotherapeutics Reports First Quarter 2024 Operating and Financial Results
Calidi Biotherapeutics Reports First Quarter 2024 Operating and Financial Results. Three upcoming posters, including an update from ongoing Phase 1 trial of Calidi's CLD-101 program, to be presented at 2024 ASCO Annual Meeting. Calidi is a clinical-stage biotechnology company developing a new generation of targeted immunotherapies. The company reported a net loss of $ million for the first quarter of 2024.
Dow Jones · 6d ago
Press Release: Calidi Biotherapeutics Reports -2-
Three months ended March 31, the company has a total of 21,978 liabilities. The company's total liabilities include liabilities related to the company's share-based compensation, contingent liabilities, and other noncurrent liabilities. The company reported a net loss for the first quarter of $7.2 million. The Company's net income for the quarter was $2.1 million. For the three months ending March 31 the company recorded a loss of $1.1 billion.
Dow Jones · 6d ago
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Aesthetic Medical Intl (NASDAQ:AIH) shares moved upwards by to $ during Monday's after-market session. The company's, Q1 earnings came out today. Harrow and Vaxart also moved upwards during the session.
Benzinga · 05/13 20:31
Weekly Report: what happened at CLDI last week (0506-0510)?
Weekly Report · 05/13 10:44
Weekly Report: what happened at CLDI last week (0429-0503)?
Weekly Report · 05/06 10:49
12 Health Care Stocks Moving In Monday's Intraday Session
Deciphera Pharmaceuticals (NASDAQ:DCPH) stock moved upwards by 72.2% to $25.22 during Monday's regular session. The company's Q1 earnings report came out today. Deciphera shares rose to $2.0 billion. SINTX Techs and Koninklijke Philips also moved upwards.
Benzinga · 04/29 16:31
Weekly Report: what happened at CLDI last week (0422-0426)?
Weekly Report · 04/29 10:54
12 Health Care Stocks Moving In Tuesday's After-Market Session
180 Life Sciences (NASDAQ:ATNF) shares moved upwards by 7.4% to $2.04 during Tuesday's after-market session. ABVC BioPharma and Medpace Hldgs stock increased by 5.15%. Fresh2 Group shares fell 12.9% during the session.
Benzinga · 04/23 20:31
Weekly Report: what happened at CLDI last week (0415-0419)?
Weekly Report · 04/22 10:46
Calidi Biotherapeutics Shares Informative Investor Presentation Slides
TipRanks · 04/19 21:43
More
Webull provides a variety of real-time CLDI stock news. You can receive the latest news about Calidi Biotherapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About CLDI
Calidi Biotherapeutics, Inc. is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's novel stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Its clinical-stage off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses. Its preclinical off-the-shelf enveloped virotherapies are designed to target disseminated solid tumors. This dual approach shall potentially treat, or even prevent, metastatic disease. Its product candidates include CLD-101 for Recurrent HGG; CLD-201 for Advanced Solid Tumors, and CLD-400 (RTNova) for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline product candidates, the Company's is also engaged in discovery research of CLD-301 (AAA) for multiple Indications.